MR-Guided Microwave Ablation in T1 Renal Cell Carcinoma: Initial Results in Clinical Routine.
Adult
Aged
Carcinoma, Renal Cell
/ pathology
Female
Glomerular Filtration Rate
Hematoma
Humans
Hydrothorax
Kidney Neoplasms
/ pathology
Male
Microwaves
/ therapeutic use
Middle Aged
Psoas Muscles
Radiofrequency Ablation
/ methods
Renal Insufficiency
Retrospective Studies
Tomography, X-Ray Computed
Treatment Outcome
Ultrasonography
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2021
2021
Historique:
received:
10
01
2021
accepted:
03
05
2021
entrez:
31
5
2021
pubmed:
1
6
2021
medline:
21
9
2021
Statut:
epublish
Résumé
Percutaneous tumor ablation is usually performed using computed tomography (CT) or ultrasound (US) guidance, although reliable visualization of the target tumor could be challenging. Magnetic resonance- (MR-) guided ablation provides more reliable visualization of the target tumors and allows multiplanar imaging of the treatment process, making it the modality of choice, in particular if lesions are small. From March 2016 to January 2018, 32 patients scheduled for percutaneous treatment of T1 RCC underwent MR-guided MWA. Complications were classified according to the Clavien grade. Kaplan-Meier survival estimates were calculated to evaluate progression-free survival (PFS). Technical success was achieved in all lesions. The mean energy and procedure duration were 61.6 ± 8.7 kJ and 118.2 ± 26.7 min, respectively. The glomerular filtration rate (GFR) dropped rapidly after 1 month of treatment and slowly recovered within three months ( Microwave ablation is feasible under MR guidance and provides effective treatment of RCC in one session.
Identifiants
pubmed: 34055980
doi: 10.1155/2021/5537192
pmc: PMC8147533
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5537192Informations de copyright
Copyright © 2021 Zhaonan Li et al.
Déclaration de conflit d'intérêts
The authors declare they have no conflicts of interest.
Références
Eur Radiol. 2017 Apr;27(4):1467-1476
pubmed: 27553935
Radiology. 2020 Sep;296(3):687-695
pubmed: 32633677
J Vasc Interv Radiol. 2008 Sep;19(9):1311-20
pubmed: 18725094
Eur Radiol. 2008 Jul;18(7):1449-55
pubmed: 18351355
Invest Radiol. 2005 Sep;40(9):583-90
pubmed: 16118551
Radiology. 2017 Jul;284(1):272-280
pubmed: 28076721
Eur Urol. 2019 May;75(5):799-810
pubmed: 30803729
J Magn Reson Imaging. 2019 Feb;49(2):374-381
pubmed: 30221797
Int J Hyperthermia. 2020;37(1):349-355
pubmed: 32286087
Korean J Radiol. 2018 Sep-Oct;19(5):938-949
pubmed: 30174484
Radiology. 2020 Mar;294(3):698-706
pubmed: 31961239
Invest Radiol. 2013 Jun;48(6):437-44
pubmed: 23511191
Int J Hyperthermia. 2020;37(1):192-201
pubmed: 32066293
Acad Radiol. 2020 Oct 12;:
pubmed: 33060007
World J Urol. 2017 May;35(5):753-759
pubmed: 27520385
IEEE Trans Biomed Eng. 2019 Jan;66(1):257-262
pubmed: 29993418
Int J Hyperthermia. 2019 Oct;36(2):21-30
pubmed: 31537160
Int J Hyperthermia. 2019;36(1):1216-1222
pubmed: 31814474
AJR Am J Roentgenol. 2019 Mar 12;:1-9
pubmed: 30860902
Cancer Imaging. 2020 Jan 30;20(1):13
pubmed: 32000862
J Endourol. 2014 Sep;28(9):1046-52
pubmed: 24846329
BJU Int. 2019 Jan;123(1):42-50
pubmed: 30019484
Int J Clin Oncol. 2019 Jun;24(6):694-697
pubmed: 30758764
Int J Hyperthermia. 2020;37(1):827-835
pubmed: 32635839
AJR Am J Roentgenol. 2021 Jan;216(1):117-124
pubmed: 32603227